Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Global Hypercholesterolemia Drugs Market 2016-2020

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver. The analysts forecast global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the ......
$2500

Global Wellness Tourism Market 2016-2020

People traveling to domestic or foreign locations and staying for not more than one consecutive year for business, leisure, and other purposes are defined as tourists. Tourism is one of the major sources of income for many countries. It positively affects the economy of both the source and host countries. The analysts forecast global wellness tourism market to grow at a CAGR of -10.69% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global wellness tourism market for 2016-2020. To calculate the market size, the report considers the revenue generated from healthy diet and weight management, physical fitness and sports, beauty treatments, relaxation and stress relief, meditation, yoga, health-related educatio......
$2500

Global Connected Health Market 2016-2020

Connected health focuses on optimizing available healthcare resources to facilitate personalized, flexible options for client-physician interaction and self-care. It uses technology to deliver healthcare services remotely. Connected health programs leverage advanced technologies like connected devices using established cellular networks to offer solutions such as telehealth, home care, and disease and lifestyle management to improve healthcare for chronic conditions. The analysts forecast global connected health market to grow at a CAGR of 26.54% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global connected health market for 2016-2020. To calculate the market size, the report considers the revenue genera......
$2500

Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020

COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing. The analysts forecast global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the ......
$2500

Global Tissue Banking Market 2016-2020

Tissue banks are biorepositories for the preservation of human and animal tissues used for disease diagnosis, biodiversity studies, and research. These banks help in the storage of various types of tissue samples such as skin, bone, cornea, heart valves, umbilical cord, and human soft tissues. Tissue banks vary significantly in size, with tissue banks in medical institutions storing a moderate number of samples while national tissue banks store a large number of samples. These samples are used to support research, particularly studies in genetic disorders, personalized medicine, and stem cell research for treating genetic conditions and maintaining and updating age demographic databases. The analysts forecast global tissue banking market for emerging applications to grow at a CAGR of 5.......
$2500

Global Scar Treatment Market 2016-2020

A scar is a patch of fibrous tissue (containing a protein called collagen) that is formed over a wound as a consequence of the body's natural healing process. Scars are classified into keloid scars, contracture scars, hypertrophic scars, and atrophic scars based on the composition of collagen and appearance. Many non-invasive methods including chemical and physical treatment and invasive methods such as surgery are used to treat different types of scars. The analysts forecast global scar treatment market to grow at a CAGR of 10.43% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the Global Scar Treatment Market 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of......
$2500

Global Intravenous Product Packaging Market 2016-2020

IV products are used in the assisting, preventing, and treatment of various disorders, including ostomy, cancer, respiratory, and ophthalmic diseases. It includes products like catheters, cannulas, and IV fluid bags. They are used to deliver nutrients, fluids, and drugs such as antibiotics, analgesics, and antipyretics. They are also used for blood transfusions and to correction of electrolyte imbalances in patients. These products use the intravenous route of administration that allows rapid delivery of medication and fluids. The analysts forecast global IV (intravenous) product packaging market to grow at a CAGR of 6.16% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global IV (intravenous) product packa......
$2500

Global Vials Primary Packaging Market 2016-2020

A vial is a small vessel made of glass or plastic, mainly used for storing a medicinal solution, drug, or powder. It is the most prevalent healthcare packaging solution. Since packaging of medicines is a complex process because of their molecular and chemical structures, they need to be packed in protective and durable materials to prevent contamination. The evolution of new diseases and increased health awareness have brought a transformation in the vial packaging market. Companies are making use of high-tech glasses and green plastics to keep medicines safe and are prioritizing environmentally-friendly products. The analysts forecast global vials primary packaging market to grow at a CAGR of 11.73% during the period 2016-2020. Covered in this report The report covers the present......
$2500

Global Meningococcal Vaccines Market 2016-2020

Meningitis (meningococcal diseases) is characterized by inflammation of the protective lining (meninges) present around the brain and spinal cord. It can be classified into infectious and non-infectious meningitis. Based on the types of organism, infectious meningitis is sub-divided into bacterial meningitis, viral meningitis, fungal meningitis, and parasitic meningitis. Bacterial meningitis occurs due to bacterial species such as hemophilus influenzae, listeria monocytogenes, neisseria meningitidis, and streptococcus pneumoniae. The analysts forecast global meningococcal vaccines market to grow at a CAGR of 13.07% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global meningococcal vaccines market for 2016......
$2500

Global Systemic Psoriasis Therapeutics Market 2016-2020

About the Systemic Psoriasis Therapeutics Market Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years). Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it i......
$2500